A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
· 14 ON SITE VISITS
· 6 ON SITE VISITS IN FIRST 7 MONTHS
· PHONE CALL APPROX EVERY 5 WEEKS
· 36 E-DIARY ENTRIES
· ONCE A WEEK E-DIARIES
· 3 INJECTION ADMINISTRATIONS
· TOTAL LENGTH OF TRIAL 30 MONTHS